SG&A expenses for the current quarter were $16.5 million, representing an increase of 32% compared to the same period last year. This change was primarily driven by a $2.5 million increase in compensation expenses, mainly as a result of increased headcount, a $0.8 million increase in marketing and advertising expenses associated with the commercialization of Barro Stem in the U.S., a $0.4 million increase in travel expenses, and a $0.3 million increase in non-cash stock-based compensation expense.

Jul 25, 2023 / CFO / receipt, needs a key / Jared Oshime, CFO | earnings call 2023-07-25 | transcript 604d6024-ce6d-4fcb-ab97-cec1ab3bbc4f | chars 8277-8779 | segment 8